



Novel Aspects of Molecular Targets for Antidepressant Drugs

Guest Editor:

Dr. Qingzhong Wang

Institute of Chinese Materia
Medica, Shanghai University of
Traditional Chinese Medicine,
Shanghai 201203, China

Deadline for manuscript
submissions:

closed (30 September 2023)

Message from the Guest Editor

Major depressive disorder (MDD) is the third leading cause of disability worldwide and can have a tremendous impact on quality of life. For half a century, clinical antidepressants have acted with therapeutic effect by regulating monoamine transmitters, inhibiting the reuptake of 5-HT and NE, and increasing the levels of 5-HT, NE, or DA in the presynaptic membrane. But problems still exist. Recently, rapid-acting antidepressants, represented by ketamine, have received much attention. The possible mechanism is related to blocking NMDA receptors and activating AMPA receptors. This research topic investigates glutamatergic receptors such as NMDA, APMA, and GluR and the related fast-acting antidepressant mechanisms. The contents mainly include the three aspects: (1) use of artificial intelligence and computational design approaches to discover powerful fast-acting compounds that bind to the glutamate receptor; (2) novel approaches, including CRISPR/cas9 and multi-omics methods, have been used to explore the biological mechanism; and (3) new multi-target antidepressants (including melatonin receptor agonists, GABA receptor modulators, etc.), medicinal plants and their extracts.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical
Biology and Phytochemistry,
University of Münster,
Corrensstrasse 48, D-48149
Münster, Germany

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), [Reaxys](#), [CaPlus / SciFinder](#), [MarinLit](#), [AGRIS](#), and [other databases](#).

Journal Rank: JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Contact Us

Molecules Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/molecules
molecules@mdpi.com
[X@Molecules_MDPI](https://twitter.com/Molecules_MDPI)